Therapeutic Asset Ratings

515 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Letrozole ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
LEUPROLIDE ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Olaparib Complete Response	AstraZeneca	P3	B (60)
Olaparib FIGO Stage III-IV	AstraZeneca	P3	B (60)
Olaparib First Line Platinum Chemotherapy	AstraZeneca	P3	B (60)
Olaparib Partial Response	AstraZeneca	P3	B (60)
Palbociclib ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Puxitatug Samrotecan Malignant Solid Tumour	AstraZeneca	P3	B (60)
Ribociclib ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Rilvegostomig Endometrial Cancer	AstraZeneca	P3	B (60)
Surovatamig Follicular Lymphoma	AstraZeneca	P3	B (60)
(+)-VINCRISTINE Large B-cell Lymphoma	AstraZeneca	P3	B (60)
VOLITINIB Enzyme Inhibitors	AstraZeneca	P3	B (60)
VOLITINIB Kidney Diseases	AstraZeneca	P3	B (60)
VOLITINIB Kidney Neoplasms	AstraZeneca	P3	B (60)
VOLITINIB Protein Kinase Inhibitors	AstraZeneca	P3	B (60)
VOLITINIB Urologic Neoplasms	AstraZeneca	P3	B (60)
Zoladex ER-Positive HER2-Negative Breast Cancer	AstraZeneca	P3	B (60)
Datopotamab Deruxtecan Biliary Cancer	AstraZeneca	P2	B (60)
Epirubicin Recurrent Angioimmunoblastic T-Cell Lymphoma	AstraZeneca	P2	B (60)
Pembrolizumab Recurrent Angioimmunoblastic T-Cell Lymphoma	AstraZeneca	P2	B (60)
Durvalumab Advanced Solid Tumours	AstraZeneca	P1/2	B (60)
Acalabrutinib Large B-cell Lymphoma	AstraZeneca	P3	B (59)
Inno-206 Advanced Solid Tumor	AstraZeneca	P3	B (59)
su011248 Enzyme Inhibitors	AstraZeneca	P3	B (59)

Showing 76 to 100 of 515 assets